{
    "name": "peginterferon alfa 2b",
    "comment": "Rx",
    "other_names": [
        "PEG Intron",
        "PegIntron Redipen",
        "Sylatron"
    ],
    "classes": [
        "Hepatitis B/Hepatitis C Agents"
    ],
    "source": "https://reference.medscape.com/drug/peg-intron-sylatron-peginterferon-alfa-2b-342617",
    "pregnancy": {
        "common": [
            "Available human data on use in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes",
            "Verify pregnancy status in females of reproductive potential prior to initiating treatment",
            "Drug may be used in combination with ribavirin; if administered with ribavirin, the information for ribavirin regarding pregnancy testing, contraception, and infertility also applies to this combination regimen; refer to ribavirin prescribing information for additional information"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Treatment may cause embryo-fetal harm when administered to a pregnant woman; advise female patients of reproductive potential to use effective contraception during treatment and for at least 10 days after final dose"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Based on animal fertility studies conducted in female cynomolgus monkeys, drug may impair human fertility; effects have been shown to be reversible"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "Based on findings from animal studies, treatment can cause embryo-fetal harm when administered to a pregnant woman; administration of nonpegylated interferon alfa-2b was abortifacient in rhesus monkeys at doses approximately 13 times higher than recommended dose of 6 mcg/kg/week; premature infant death was also observed"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of peginterferon alfa-2b in human or animal milk, or on its effects on the breastfed infant, or milk production; nonpegylated interferon alfa 2-b is present in human milk at low levels; developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for treatment and any potential adverse effects from treatment on breastfed infant or from underlying maternal condition",
            "Therapy may be used in combination with ribavirin; if drug is administered with ribavirin, breastfeeding is not recommended because of potential for serious adverse reactions from ribavirin in the breastfed infant"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Alfa interferons cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders",
                "The risk of serious depression, with suicidal ideation and completed suicides, and other serious neuropsychiatric disorders are increased with alpha interferons",
                "Discontinue drug if persistently severe or worsening signs or symptoms of the above conditions are present; disorders typically resolve after stopping therapy",
                "These disorders may not resolve after the drug is discontinued",
                "Monitored closely with periodic clinical and laboratory evaluations"
            ],
            "specific": [
                {
                    "type": "Combination therapy with ribavirin ",
                    "description": [
                        "Ribavirin may cause birth defects and/or fetal death",
                        "Extreme care must be taken to avoid pregnancy in women taking peginterferon alfa-2a and in female partners of men taking peginterferon alfa-2a",
                        "Ribavirin causes hemolytic anemia; associated anemia may result in worsening of cardiac disease",
                        "Because ribavirin is genotoxic and mutagenic, consider it a potential carcinogen"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Autoimmune hepatitis",
                "Decompensated liver disease (Child-Pugh >6 [class B and C])"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "May cause/aggravate fatal or life threatening autoimmune, ischemic, and infectious disorders",
                "Life-threatening or fatal neuropsychiatric events, including suicide, suicidal and homicidal ideation, depression, relapse of drug addiction/overdose, and aggressive behavior sometimes directed towards others reported in patients with and without a previous psychiatric disorder during therapy and follow-up; psychoses, hallucinations, bipolar disorders, and mania have been observed in patients receiving this therapy and should be used with caution in patients with a history of psychiatric disorders; report any symptoms of depression or suicidal ideation to healthcare provider",
                "Monitor and evaluate patients for signs and symptoms of depression and other psychiatric symptoms every 3 weeks during first 8 weeks of treatment and every 6 months thereafter; monitor patients during treatment and for at least 6 months after last dose; permanently discontinue therapy for suicidal or homicidal ideation, aggressive behavior towards others, or other severe or persistent psychiatric symptoms (see Black Box Warnings)",
                "Caution with hypothyroidism, hyperthyroidism, hyperglycemia, and diabetes mellitus that cannot be effectively treated by medication",
                "Cardiac adverse reactions occurred in 4% of patients during clinical trials; permanently discontinue with new onset ventricular arrhythmia or cardiovascular decompensation",
                "Risk of visual impairment and retinal disorders; discontinue if ophthalmologic problems develop",
                "Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonitis, pulmonary hypertension, and sarcoidosis, some resulting in respiratory failure or patient deaths, may be induced or aggravated by therapy; recurrence of respiratory failure has been observed with interferon rechallenge; monitor",
                "Ischemic and hemorrhagic cerebrovascular events observed",
                "Development or exacerbation of autoimmune disorders (e.g., thyroiditis, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, rheumatoid arthritis, interstitial nephritis, systemic lupus erythematosus, and psoriasis) observed; use with caution in patients with autoimmune disorders",
                "Pancreatitis and ulcerative or hemorrhagic/iscemic colitis may occur",
                "Severe decreases in neutrophil or platelet counts reported",
                "May cause birth defects and fetal death: use extreme care to avoid pregnancy in female patients and female partners of male patients",
                "When administered in combination with ibavirin causes hemolytic anemia; associated anemia may result in worsening of cardiac disease",
                " Hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including peginterferon alpha 2b; cirrhotic CHC patients co-infected with HIV receiving highly active antiretroviral therapy (HAART) and alpha interferons with or without ribavirin appear to be at increased risk for development of hepatic decompensation compared to patients not receiving HAART; monitor clinical status and hepatic function during treatment and discontinue immediately if decompensation (Child-Pugh score greater than 6) observed",
                "Monitor closely patients with impaired renal function, for signs and symptoms of interferon toxicity, including increases in serum creatinine; adjust dose or discontinue therapy accordingly",
                "Serious, acute hypersensitivity reactions and cutaneous eruptions reported ",
                "Dental/periodontal disorders reported with combination therapy",
                "Hypertriglyceridemia may result in pancreatitis (e.g., triglycerides greater than 1000 mg/dL)",
                "Weight loss and growth inhibition reported during combination therapy in pediatric patients",
                "Long-term growth inhibition (height) reported in some patients",
                "Peripheral neuropathy observed when used in combination with telbivudine"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "deferiprone",
            "description": {
                "common": "deferiprone, peginterferon alfa 2b.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis; if an alternative is not possible, monitor absolute neutrophil count more frequently."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pexidartinib",
            "description": {
                "common": "peginterferon alfa 2b and pexidartinib both increase  Other (see comment). Avoid or Use Alternate Drug. Pexidartinib can cause hepatotoxicity. Avoid coadministration of pexidartinib with other products know to cause hepatoxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pretomanid",
            "description": {
                "common": "peginterferon alfa 2b, pretomanid.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Pretomanid regimen associated with hepatotoxicity. Avoid alcohol and hepatotoxic agents, including herbal supplements and drugs other than bedaquiline and linezolid."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acalabrutinib",
            "description": {
                "common": "acalabrutinib, peginterferon alfa 2b.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may increase risk of myelosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aldesleukin",
            "description": {
                "common": "peginterferon alfa 2b increases toxicity of aldesleukin by unknown mechanism. Use Caution/Monitor. Interferons may enhance the adverse effects of aldesleukin including myocardial and renal toxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "peginterferon alfa 2b, amitriptyline. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amoxapine",
            "description": {
                "common": "peginterferon alfa 2b, amoxapine. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "peginterferon alfa 2b, aripiprazole. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atomoxetine",
            "description": {
                "common": "peginterferon alfa 2b, atomoxetine. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bosentan",
            "description": {
                "common": "peginterferon alfa 2b decreases levels of bosentan by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celecoxib",
            "description": {
                "common": "peginterferon alfa 2b decreases levels of celecoxib by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "peginterferon alfa 2b, chlorpromazine. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "peginterferon alfa 2b decreases levels of chlorpropamide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clomipramine",
            "description": {
                "common": "peginterferon alfa 2b, clomipramine. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "codeine",
            "description": {
                "common": "peginterferon alfa 2b, codeine. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dapsone",
            "description": {
                "common": "peginterferon alfa 2b decreases levels of dapsone by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desipramine",
            "description": {
                "common": "peginterferon alfa 2b, desipramine. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextromethorphan",
            "description": {
                "common": "peginterferon alfa 2b, dextromethorphan. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diclofenac",
            "description": {
                "common": "peginterferon alfa 2b decreases levels of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxepin",
            "description": {
                "common": "peginterferon alfa 2b, doxepin. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "duloxetine",
            "description": {
                "common": "peginterferon alfa 2b, duloxetine. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etravirine",
            "description": {
                "common": "peginterferon alfa 2b decreases levels of etravirine by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flecainide",
            "description": {
                "common": "peginterferon alfa 2b, flecainide. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "peginterferon alfa 2b, fluoxetine. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvastatin",
            "description": {
                "common": "peginterferon alfa 2b decreases levels of fluvastatin by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "fluvoxamine, peginterferon alfa 2b. Other (see comment). Use Caution/Monitor. \nComment: Therapeutic effect may be altered with coadministration of CYP2D6 substrates; peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glimepiride",
            "description": {
                "common": "peginterferon alfa 2b decreases levels of glimepiride by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glipizide",
            "description": {
                "common": "peginterferon alfa 2b decreases levels of glipizide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glyburide",
            "description": {
                "common": "peginterferon alfa 2b decreases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haloperidol",
            "description": {
                "common": "peginterferon alfa 2b, haloperidol. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen",
            "description": {
                "common": "peginterferon alfa 2b decreases levels of ibuprofen by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen IV",
            "description": {
                "common": "peginterferon alfa 2b decreases levels of ibuprofen IV by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ifosfamide, peginterferon alfa 2b.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Ifosfamide may enhance the toxicities of myelosuppressive agents. Monitor for increased risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imipramine",
            "description": {
                "common": "peginterferon alfa 2b, imipramine. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indomethacin",
            "description": {
                "common": "peginterferon alfa 2b decreases levels of indomethacin by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lamivudine",
            "description": {
                "common": "peginterferon alfa 2b, lamivudine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of liver decompensation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "losartan",
            "description": {
                "common": "peginterferon alfa 2b decreases levels of losartan by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maprotiline",
            "description": {
                "common": "peginterferon alfa 2b, maprotiline. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methadone",
            "description": {
                "common": "peginterferon alfa 2b will increase the level or effect of methadone by  unknown mechanism. Use Caution/Monitor. Methadone levels may be elevated, increasing the pharmacologic effects and adverse reactions. Monitor patients for signs and symptoms of increased narcotic effects and adjust methadone dose as needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methamphetamine",
            "description": {
                "common": "peginterferon alfa 2b, methamphetamine. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metoprolol",
            "description": {
                "common": "peginterferon alfa 2b, metoprolol. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mexiletine",
            "description": {
                "common": "peginterferon alfa 2b, mexiletine. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mirtazapine",
            "description": {
                "common": "peginterferon alfa 2b, mirtazapine. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "montelukast",
            "description": {
                "common": "peginterferon alfa 2b decreases levels of montelukast by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "naproxen",
            "description": {
                "common": "peginterferon alfa 2b decreases levels of naproxen by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nateglinide",
            "description": {
                "common": "peginterferon alfa 2b decreases levels of nateglinide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nortriptyline",
            "description": {
                "common": "peginterferon alfa 2b, nortriptyline. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "palonosetron",
            "description": {
                "common": "peginterferon alfa 2b, palonosetron. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paroxetine",
            "description": {
                "common": "peginterferon alfa 2b, paroxetine. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pegloticase",
            "description": {
                "common": "pegloticase will decrease the level or effect of peginterferon alfa 2b by  Other (see comment). Use Caution/Monitor. According to the manufacturer, potential for anti-PEG antibody development that may bind to other pegylated drugs; clinical significance unknown"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pegvaliase",
            "description": {
                "common": "pegvaliase, peginterferon alfa 2b. Other (see comment). Use Caution/Monitor. \nComment: The majority of patients treated with pegvaliase develop anti-polyethylene glycol (PEG) IgM and IgG antibodies. Risk of coadministration with different PEGylated products is unknown. There is a case report of anaphylaxis following a medroxyprogesterone acetate injectable suspension that contained PEG 3350. Carefully read all drug labels, including OTC drugs to check contents for PEG. Note: Unable to include an exhaustive product list for this interaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perphenazine",
            "description": {
                "common": "peginterferon alfa 2b, perphenazine. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "peginterferon alfa 2b decreases levels of phenytoin by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "promethazine",
            "description": {
                "common": "peginterferon alfa 2b, promethazine. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propafenone",
            "description": {
                "common": "peginterferon alfa 2b, propafenone. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propranolol",
            "description": {
                "common": "peginterferon alfa 2b, propranolol. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "protriptyline",
            "description": {
                "common": "peginterferon alfa 2b, protriptyline. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "risperidone",
            "description": {
                "common": "peginterferon alfa 2b, risperidone. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ritonavir",
            "description": {
                "common": "peginterferon alfa 2b, ritonavir. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate. The concomitant use of interferons and anti-retroviral protease inhibitors should be done with caution as both can cause hepatic damage. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sertraline",
            "description": {
                "common": "peginterferon alfa 2b, sertraline. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tamoxifen",
            "description": {
                "common": "peginterferon alfa 2b decreases levels of tamoxifen by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "theophylline",
            "description": {
                "common": "peginterferon alfa 2b increases levels of theophylline by unknown mechanism. Use Caution/Monitor. Alpha interferons may decrease the clearance of theophylline resulting in increased plasma concentrations."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thioridazine",
            "description": {
                "common": "peginterferon alfa 2b, thioridazine. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "timolol",
            "description": {
                "common": "peginterferon alfa 2b, timolol. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "peginterferon alfa 2b decreases levels of tolbutamide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolterodine",
            "description": {
                "common": "peginterferon alfa 2b, tolterodine. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "torsemide",
            "description": {
                "common": "peginterferon alfa 2b decreases levels of torsemide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tramadol",
            "description": {
                "common": "peginterferon alfa 2b, tramadol. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trazodone",
            "description": {
                "common": "peginterferon alfa 2b, trazodone. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimipramine",
            "description": {
                "common": "peginterferon alfa 2b, trimipramine. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "venlafaxine",
            "description": {
                "common": "peginterferon alfa 2b, venlafaxine. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voriconazole",
            "description": {
                "common": "peginterferon alfa 2b decreases levels of voriconazole by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "peginterferon alfa 2b increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zafirlukast",
            "description": {
                "common": "peginterferon alfa 2b decreases levels of zafirlukast by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zidovudine",
            "description": {
                "common": "peginterferon alfa 2b will increase the level or effect of zidovudine by  Other (see comment). Use Caution/Monitor. Interferons may enhance adverse effects of zidovudine including increased myelosuppression."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "56"
        },
        {
            "name": "Fatigue",
            "percent": "52"
        },
        {
            "name": "Injection site inflammation",
            "percent": "47"
        },
        {
            "name": "reaction",
            "percent": "16-29"
        },
        {
            "name": "Depression",
            "percent": "28"
        },
        {
            "name": "Anxiety",
            "percent": "26"
        },
        {
            "name": "emotional lability",
            "percent": "23"
        },
        {
            "name": "irritability",
            "percent": "22"
        },
        {
            "name": "Nausea",
            "percent": "22"
        },
        {
            "name": "Insomnia",
            "percent": "20"
        },
        {
            "name": "Alopecia",
            "percent": "18"
        },
        {
            "name": "Fever",
            "percent": "15"
        },
        {
            "name": "Anorexia",
            "percent": "12"
        },
        {
            "name": "Diarrhea",
            "percent": "5-12"
        },
        {
            "name": "Abdominal pain",
            "percent": "12"
        },
        {
            "name": "Dizziness",
            "percent": "12"
        },
        {
            "name": "Impaired concentration",
            "percent": "11"
        },
        {
            "name": "Pain",
            "percent": "11"
        },
        {
            "name": "Pruritus",
            "percent": "94"
        },
        {
            "name": "Dry skin",
            "percent": "77"
        },
        {
            "name": "Weight loss",
            "percent": "75"
        },
        {
            "name": "Fatigue",
            "percent": "70"
        },
        {
            "name": "ALT or AST increased",
            "percent": "69"
        },
        {
            "name": "Pyrexia",
            "percent": "68"
        },
        {
            "name": "Headache",
            "percent": "64"
        },
        {
            "name": "Anorexia",
            "percent": "51"
        },
        {
            "name": "Myalgia",
            "percent": "63"
        },
        {
            "name": "Nausea",
            "percent": "62"
        },
        {
            "name": "Arthralgia",
            "percent": "59"
        },
        {
            "name": "Chills",
            "percent": "38"
        },
        {
            "name": "Injection site reactions",
            "percent": "37"
        },
        {
            "name": "Depression",
            "percent": "36"
        },
        {
            "name": "Dysgeusia",
            "percent": "35"
        },
        {
            "name": "Diarrhea",
            "percent": "34"
        },
        {
            "name": "Exfoliative rash",
            "percent": "26"
        },
        {
            "name": "Dizziness",
            "percent": "23"
        },
        {
            "name": "Alopecia",
            "percent": "23"
        },
        {
            "name": "Vomiting",
            "percent": "21"
        },
        {
            "name": "Olfactory nerve disorder",
            "percent": "11"
        },
        {
            "name": "Blood alkaline phosphatase increased",
            "percent": "10"
        },
        {
            "name": "Paraesthesia",
            "percent": "10"
        },
        {
            "name": "Weight loss",
            "percent": "8"
        },
        {
            "name": "Pharyngitis",
            "percent": "7"
        },
        {
            "name": "Transient increase in transaminases",
            "percent": "7"
        },
        {
            "name": "Malaise",
            "percent": "7"
        },
        {
            "name": "Dermatitis",
            "percent": "6"
        },
        {
            "name": "Sinusitis",
            "percent": "6"
        },
        {
            "name": "Vomiting",
            "percent": "6"
        },
        {
            "name": "Dyspepsia",
            "percent": "6"
        },
        {
            "name": "Flushing",
            "percent": "5"
        },
        {
            "name": "Hepatomegaly",
            "percent": "5"
        },
        {
            "name": "Rash",
            "percent": "2"
        },
        {
            "name": "Hypertonia",
            "percent": "8"
        },
        {
            "name": "Hypothyroidism",
            "percent": "7"
        },
        {
            "name": "Injection site pain",
            "percent": "6"
        },
        {
            "name": "Taste perversion",
            "percent": "6"
        },
        {
            "name": "Neutropenia",
            "percent": "5"
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "GGT increased",
            "percent": null
        },
        {
            "name": "Proteinuria",
            "percent": null
        },
        {
            "name": "Anemia",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "Cough",
            "percent": null
        },
        {
            "name": "Colitis",
            "percent": null
        },
        {
            "name": "Pancreatitis",
            "percent": null
        },
        {
            "name": "Autoimmune thrombocytopenia",
            "percent": null
        },
        {
            "name": "Blindess",
            "percent": null
        },
        {
            "name": "thrombosis of retinal vein",
            "percent": null
        },
        {
            "name": "Aggressive behavior",
            "percent": null
        },
        {
            "name": "Depression",
            "percent": null
        },
        {
            "name": "Homicidal thoughts",
            "percent": null
        },
        {
            "name": "suicidal thoughts",
            "percent": null
        },
        {
            "name": "suicide",
            "percent": null
        },
        {
            "name": "As with all proteins",
            "percent": null
        },
        {
            "name": "there is a potential for immunogenicity",
            "percent": null
        },
        {
            "name": "Pulmonary fibrosis",
            "percent": null
        },
        {
            "name": "Bacterial infection including sepsis",
            "percent": null
        },
        {
            "name": "Hepatitis B virus reactivation in HCV",
            "percent": null
        },
        {
            "name": "HBV co",
            "percent": null
        },
        {
            "name": "infected patients",
            "percent": null
        },
        {
            "name": "Pericarditis",
            "percent": null
        },
        {
            "name": "Aphthous stomatitis",
            "percent": null
        },
        {
            "name": "Tongue pigmentation",
            "percent": null
        }
    ]
}